Optic Neuritis – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Optic Neuritis Emerging Therapy and TPP Insights

Thelansis’s “Optic Neuritis Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Optic Neuritis Overview

Optic neuritis is an inflammatory optic-nerve disorder that can cause subacute vision loss, pain on eye movement, impaired color vision, and visual-field defects. It may occur with multiple sclerosis, aquaporin-4 antibody-associated neuromyelitis optica spectrum disorder, MOG-antibody-associated disease, or other inflammatory, infectious, and less common causes. Diagnosis relies on eye and neurological examination, MRI, and targeted antibody testing when indicated. High-dose corticosteroids can accelerate visual recovery; severe or steroid-unresponsive attacks may require early plasma exchange, particularly in NMOSD or MOGAD. Recovery varies, and some patients retain visual deficits or experience recurrence. Long-term treatment depends on the underlying cause and may include disease-specific immunotherapy. Remyelination and neuroprotection remain investigational; a 2026 review found no phase 3 trial in either area met its primary endpoint. Early diagnosis supports better targeted care.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
  • Pipeline analysis
  • Target patients for emerging therapies
  • Key companies
  • Key mechanism of actions
  • Launch date estimates, etc.
• Clinical trial landscape analysis
  • Target patient segments
  • Trial endpoints
  • Trial design
  • Recruitment criteria, etc.
• Unmet Needs and Opportunities
  • Performance of key current therapies
  • Top areas of unmet needs
  • Opportunity sizing for key unmet needs
• Target Product Profiles
  • Attributes and levels
  • Physician likelihood of prescribing
  • Expected patient shares
• KOL insights on key emerging therapies
  • Level of awareness
  • Expected use / line of therapy
  • Extent to fulfil key unmet needs
  • KOL quotes

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key emerging therapies – profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Current challenges
  • Unmet needs
• Emerging therapies
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)